The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies
Zunyuan Li, Xiyu Wang, Qin Shi, Yuhong Guo, Guirong Dong, Zhidan Liu · 2026
Read The clinical trial landscape of bispecific antibodies in non-small cell lung cancer: mechanistic trends and developmental strategies by Zunyuan Li, Xiyu Wang, Qin Shi, Yuhong Guo, Guirong Dong, Zhidan Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13581824.txt.
Description
Zunyuan Li and five co-authors map in 2026 the clinical trials of bispecific antibodies for non-small cell lung cancer. This common lung cancer often learns to resist targeted drugs, and many tumors shut out the immune-based drugs known as checkpoint inhibitors.
Bispecific antibodies grab two targets at once, which can block escape routes and wake up the immune response inside the tumor. The authors systematically reviewed the trial record to chart which designs are being tested and how the field is developing. Their survey shows where this approach stands and which strategies drug developers are betting on next.
Catalog record
| CREATOR | Zunyuan Li, Xiyu Wang, Qin Shi, Yuhong Guo, Guirong Dong, Zhidan Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |